MURRAY HILL, N.J.—C.R. Bard Inc.'s board of directors authorized the repurchase of up to $500 million of the firm's common stock.
This authorization is in addition to the approximately $55 million remaining under the company's prior authorization, the firm said.
Share repurchases will be made from time-to-time in the open market or through privately negotiated transactions.
C.R. Bard is a developer, manufacturer and marketer of life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products headquartered in Murray Hill.